Physician profile
Robert Chang
NPI 1992894885
$4,489.75
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,015 · 2020: $2,795 · 2021: $591 · 2023: $88.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $88.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $88.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,423.72 | 2019-2021 | |
| Amgen INC. | $424.31 | 2019-2023 | Tavneos, Parsabiv |
| Vifor Pharma, INC. | $406.46 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $400.37 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $307.00 | 2019-2023 | Farxiga |
| Akebia Therapeutics INC | $130.61 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $81.01 | 2019 | |
| Mallinckrodt Hospital Products INC. | $80.08 | 2020-2021 | |
| Mallinckrodt Enterprises LLC | $78.78 | 2019 | |
| Fresenius USA Marketing, INC. | $46.49 | 2019-2021 | |
| Medtronic, INC. | $45.86 | 2023 | In.Pact Admiral |
| Bayer Healthcare Pharmaceuticals INC. | $36.50 | 2021 | |
| Dexcom, INC. | $16.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.